ClinicalTrials.gg
Not yet recruitingNCT07719257Updated Jul 22, 2026

Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD)

A Phase 1 interventional study of TUL108 and Placebo in Complicated Urinary Tract Infections(cUTI), sponsored by Zhuhai United Laboratories Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Zhuhai United Laboratories Co., Ltd. (part of The United Laboratories International Holdings Limited) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 26 studies in Urinary Tract Infections with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Urinary Tract Infections · China.

Planned enrollment
17th of 22
72 · median 150
Started
2026
with 1 other
Phase 1
4 of 26
2 open now
Registered
26th of 26
by date

Among the 26 studies in Urinary Tract Infections with a site in China, this one is the 17th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 1, and was the 26th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

6 of the 26 studies in Urinary Tract Infections with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 83 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (28%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Urinary Tract Infections with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety, tolerability and pharmacokinetics of single and multiple intravenous (IV) infusion of TUL108 in healthy participants.

Read the detailed description

Primary Objective:

To evaluate the safety and tolerability of single and multiple intravenous (IV) infusion of TUL108 in healthy participants.

Secondary Objectives:

  1. To evaluate the pharmacokinetic (PK) profiles of TUL108 following single and multiple IV infusion in healthy participants.
  2. To evaluate the effect of IV infusion of TUL108 on QT interval.
  3. To preliminarily evaluate the human biotransformation and mass balance characteristics following IV infusion of TUL108.
03

Conditions studied

  • Complicated Urinary Tract Infections(cUTI)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must sign the form prior to the study, fully understand the study, procedures, and potential adverse reactions, and be voluntary participate in and able to complete the study as required by the protocol.
  2. Male or female participants aged 18-45 years (inclusive).
  3. Body weight of not less than 50.00 kg for male participants and 45.00 kg for female participants with (BMI) within the range of 19.0-27.0 kg/m2 (inclusive).
  4. Female participants of , or male participants whose partners are of childbearing potential, must have no plans for pregnancy, sperm/egg donation from signing the informed consent until 3 months after the last dose, and must be voluntary to use highly effective (including their partners) (non-pharmacological contraception is required during the study).

Exclusion criteria

Exclusion Criteria:

  1. Having a severe disease (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, pulmonary, immunological, psychiatric, or cardiovascular and cerebrovascular diseases) within 12 months prior to screening.
  2. Participants with clinically significant abnormalities in laboratory tests, physical examination, vital signs, (ECG), posteroanterior chest X-ray, or abdominal ultrasound.
  3. Female participants who are pregnant or lactating.
  4. Participants with acute illness or requiring concomitant medication from screening to the first dose.
  5. Participants who are unable to tolerate venipuncture or have a history of needle phobia or hemophobia.
  6. Participants who are unsuitable for the study as assessed by the investigator due to any other factors.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Part1: TUL108

    A single ascending dose (SAD) of intravenous (IV) TUL108 (50mg\~1500mg)

    Drug: TUL108

  • Placebo comparator
    Part1: Placebo

    Placebo

    Drug: Placebo

  • Experimental
    Part2: TUL108

    A multiple ascending dose (MAD) of intravenous (IV) TUL108 (125 mg\~500mg q8h)

    Drug: TUL108

  • Placebo comparator
    Part2: Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugTUL108

    50 mg、125 mg、250 mg、500 mg、1000 mg、1500 mg

  • DrugPlacebo

    0.9% Sodium Chloride Injection

  • DrugTUL108

    125 mg、250 mg、500 mg

06

What researchers measure

Primary outcomes

  1. Part 1: Incidence of adverse events (AEs), serious adverse events (SAEs) etc.

    Time frame: Day 1 to Day 4

  2. Part 2: Incidence of adverse events (AEs), serious adverse events (SAEs) etc.

    Time frame: Day 1 to Day 11

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.

Of 16 phase 1 interventional studies under Urinary Tract Infections, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 22, 2026
StartEst.
Jul 30, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07719257
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Jul 30, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 22, 2026

Study contacts

Jing Zhang
Contact
13816357098@163.com
+86-021-52887926
Jing Zhang
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion